ClinicalTrials.gg
CompletedNCT00141414Updated Jan 1, 2007

To Evaluate the Long-Term Safety of Pregabalin in Refractory Partial Epilepsy.

A Phase 2 interventional study of Pregabalin in Epilepsy, Partial, sponsored by Pfizer. Completed at 25 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2007-01-01.

Sponsored by Pfizer · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
82
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 18 studies testing pregabalin in Epilepsies, Partial — none open to participants now, none under way, none of them phase 3. Pregabalin · Epilepsies, Partial.

Enrollment
13th of 18
82 · median 244
Started
1997
the only one that year
Phase 2
Only one
of the 18
Registered
1st of 18
by date
Lead sponsor
7 of 18
Pfizer

Among the 18 studies testing pregabalin in Epilepsies, Partial, this one is the 13th largest by enrollment, is the only one that started in 1997, is the only one in phase 2, and was the 1st registered.

Epilepsies, Partial

243 studies on the registry are indexed under Epilepsies, Partial; 49 are open to participants now.

Browse Epilepsies, Partial studies →

Open to participants now

None of the 18 studies testing pregabalin in Epilepsies, Partial is open now. The open studies under Epilepsies, Partial, anywhere →

About pregabalin

Pregabalin: first FDA approval 2004 (LYRICA), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 37 Epilepsies, Partial studies recruiting now, 9 (24%) set no upper age limit and 24 (65%) stop at 75 or younger; 17 take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 18 studies testing pregabalin in Epilepsies, Partial as a file.
02

Study summary

To evaluate the long-term safety of pregabalin in refractory partial epilepsy.

03

Conditions studied

  • Epilepsy, Partial

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Must have met the inclusion criteria for preceding double-blind study.
  • Have received double-blind study medication and wish to receive open-label pregabalin.

Exclusion criteria

Exclusion Criteria:

  • Pregnant or considering becoming pregnant.
  • Receiving any concomitant medication that could alter the effectiveness of their medication response or seizure frequency.
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
82 participants

Interventions

06

What researchers measure

Primary outcomes

  1. Safety

07

Study locations

25 sites
  • Pfizer Investigational Site
    Little Rock, Arkansas 72205, United States
  • Pfizer Investigational Site
    Los Angeles, California 90033, United States
  • Pfizer Investigational Site
    Stanford, California 94305, United States
  • Pfizer Investigational Site
    Miami, Florida 33136, United States
  • Pfizer Investigational Site
    Plantation, Florida 33317, United States
  • Pfizer Investigational Site
    Indianapolis, Indiana 46202, United States
  • Pfizer Investigational Site
    Indianapolis, Indiana 46254, United States
  • Pfizer Investigational Site
    Baltimore, Maryland 21201, United States
  • Pfizer Investigational Site
    Baltimore, Maryland 21287, United States
  • Pfizer Investigational Site
    Boston, Massachusetts 02215, United States
  • Pfizer Investigational Site
    Ann Arbor, Michigan 48108-0768, United States
  • Pfizer Investigational Site
    St. Paul, Minnesota 55102, United States
  • Pfizer Investigational Site
    Chesterfield, Missouri 63017, United States
  • Pfizer Investigational Site
    Bronx, New York 10467, United States
  • Pfizer Investigational Site
    New York, New York 10016, United States
  • Pfizer Investigational Site
    New York, New York 10032, United States
  • Pfizer Investigational Site
    Rochester, New York 14642, United States
  • Pfizer Investigational Site
    Winston-Salem, North Carolina 27157, United States
  • Pfizer Investigational Site
    Cleveland, Ohio 44195, United States
  • Pfizer Investigational Site
    Columbus, Ohio 43210, United States
  • Pfizer Investigational Site
    Philadelphia, Pennsylvania 19104, United States
  • Pfizer Investigational Site
    Nashville, Tennessee 37232, United States
  • Pfizer Investigational Site
    Madison, Wisconsin 53715, United States
  • Pfizer Investigational Site
    Madison, Wisconsin 53792, United States
  • Pfizer Investigational Site
    Bonn, 53105, Germany
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 1997 and a completion of Oct 2005. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 30, 2005
First posted
Sep 1, 2005
Start
Nov 1997
Completion
Oct 2005
Last update
Jan 1, 2007
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
No changes since tracking began. The registry record was last updated on Jan 1, 2007, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00141414
Lead sponsor
Pfizer
First posted
Sep 1, 2005
Start date
Nov 1997
Completion
Oct 2005
Last update
Jan 1, 2007

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2006. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pregabalin

Start the discussion